Annexon Biosciences, Inc. (ANNX)
| Market Cap | 817.44M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -102.50M |
| Shares Out | 38.33M |
| EPS (ttm) | -2.86 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 118,957 |
| Open | 21.51 |
| Previous Close | 21.83 |
| Day's Range | 20.74 - 21.71 |
| 52-Week Range | 15.52 - 38.01 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 37.00 (+76.6%) |
| Est. Earnings Date | Nov 15, 2021 |
About ANNX
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune and neurodegenerative diseases. It focuses on the treatment of body, brain, and eye disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, which has completed Phase 1b clinical trials to treat patients with guillain- barré syndrome; an...
Financial Performance
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for ANNX stock is "Strong Buy." The 12-month stock price forecast is 37.00, which is an increase of 76.61% from the latest price.
News
Annexon Biosciences to Participate in 2021 Cantor Virtual Global Healthcare Conference
CAMBRIDGE, Mass., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with...
Annexon Biosciences to Highlight Neurodegeneration Franchise in Upcoming Virtual C1q Series R&D Event
CAMBRIDGE, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with...
Annexon Biosciences Reports Second Quarter 2021 Financial Results and Provides Mid-Year Business Update
– Recently expanded Autoimmune franchise with advancement of third clinical candidate, ANX009, and strategically expanded into additional autoantibody-driven diseases –
Annexon Broadens Autoimmune Franchise with Advancement of Third Anti-C1q Product Candidate and Strategic Expansion in...
Advancing subcutaneous ANX009 candidate into Phase 1b program in Lupus Nephritis
Annexon to Present at the Raymond James Human Health Innovation Conference
SOUTH SAN FRANCISCO, Calif., June 16, 2021 (GLOBE NEWSWIRE) -- Today, Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical stage biopharmaceutical company developing a pipeline of novel therapies for ...
Moving Average Crossover Alert: Annexon (ANNX)
Annexon (ANNX) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
Annexon Biosciences Provides Business Update and Reports First Quarter 2021 Financial Results
– ANX005 Huntington's Disease Phase 2 trial fully enrolled with data anticipated 2H 2021 –
Annexon to Present at the BofA Securities 2021 Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 05, 2021 (GLOBE NEWSWIRE) -- Today Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical stage biopharmaceutical company developing a pipeline of novel therapies for pati...
Annexon Biosciences Reports Fourth Quarter and Full-Year 2020 Financial Results with Recent Business Highlights
SOUTH SAN FRANCISCO, Calif., March 25, 2021 (GLOBE NEWSWIRE) -- Today Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for pa...
Annexon Shares Gain After Patient Dosing Starts In Mid-Stage Study For Vision Loss Disorder Therapy
Annexon Inc (NASDAQ: ANNX) has commenced patient dosing in its Phase 2 ARCHER study evaluating ANX007 to treat Geographic Atrophy (GA). GA, also known as atrophic age-related macular degeneration (AMD) ...
Annexon Advances Classical Complement Platform with Initiation of Global Phase 2 ARCHER Trial in Patients with Geogra...
SOUTH SAN FRANCISCO, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Today, Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical stage biopharmaceutical company developing novel therapies for patients with c...
Annexon Welcomes William H. Carson, M.D.
Thomas G. Wiggans appointed Chairman Thomas G. Wiggans appointed Chairman
BMEZ: Healthcare Exposure With A ~4% Yield And Growth Potential
BMEZ delivered solid results throughout 2020, helped by the healthcare sector overall. This fund doesn't just invest in your typical healthcare companies though and tilts towards smaller and private inv...
Annexon Highlights Recent Achievements and Outlines Expected Key Milestones in 2021 for Its Broad Portfolio of Comple...
SOUTH SAN FRANCISCO, Calif., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical stage biopharmaceutical company developing a pipeline of novel therapies for patients ...
Annexon to Present at the J.P. Morgan 39th Annual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical stage biopharmaceutical company developing a pipeline of novel therapies for patients ...